The American Journal of Managed Care

Subcutaneous Treatments Can Save Chair Time, Decrease Infusion Reaction in NSCLC: Joshua K. Sabari, MD

Subcutaneous therapy could be the future of non–small cell lung cancer (NSCLC) as it would decrease time needed for treatment ...
Medscape

Dose Adjustment After Gaps in Subcutaneous Allergen Immunotherapy May Lead to Safer Outcomes

Down-titrating vial concentrations when restarting subcutaneous allergen immunotherapy after treatment gaps may help lower ...
The American Journal of Managed Care

Subcutaneous Ofatumumab Shows Reduced Injection Reactions in Multiple Sclerosis

New findings show a similar number of injective-related reactions (IRRs) were reported between the use of ofatumumab (Kesimpta) and ocrelizumab (Ocrevus) in the treatment of multiple sclerosis, but ...
Cure Today

Subcutaneous Opdivo Receives FDA Approval for Advanced, Metastatic Solid Tumors

Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The CHECKMATE-67T trial showed a 24% response rate for subcutaneous Opdivo ...